Last week, FDA staff raised concerns about eye-related side effects that may come with GlaxoSmithKline’s BCMA cancer treatment. Despite questions about whether those problems, which include loss of vision, so severe patients stopped reading or driving, could be effectively identified and managed, the drug came out of an advisory committee …
Read More »GSK anti-BCMA security issues? FDA panel turns a blind eye
